202 related articles for article (PubMed ID: 35034160)
21. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.
Byron SA; Gartside M; Powell MA; Wellens CL; Gao F; Mutch DG; Goodfellow PJ; Pollock PM
PLoS One; 2012; 7(2):e30801. PubMed ID: 22383975
[TBL] [Abstract][Full Text] [Related]
22. Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer.
Devis L; Moiola CP; Masia N; Martinez-Garcia E; Santacana M; Stirbat TV; Brochard-Wyart F; García Á; Alameda F; Cabrera S; Palacios J; Moreno-Bueno G; Abal M; Thomas W; Dufour S; Matias-Guiu X; Santamaria A; Reventos J; Gil-Moreno A; Colas E
J Pathol; 2017 Mar; 241(4):475-487. PubMed ID: 27873306
[TBL] [Abstract][Full Text] [Related]
23. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death.
Jamieson A; Huvila J; Chiu D; Thompson EF; Scott S; Salvador S; Vicus D; Helpman L; Gotlieb W; Kean S; Samouelian V; Köbel M; Kinloch M; Parra-Harran C; Offman S; Grondin K; Irving J; Lum A; Senz J; Leung S; McConechy MK; Plante M; Kommoss S; Huntsman DG; Talhouk A; Gilks CB; McAlpine JN
Mod Pathol; 2023 Apr; 36(4):100085. PubMed ID: 36788084
[TBL] [Abstract][Full Text] [Related]
24. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Zighelboim I; Ali S; Lankes HA; Backes F; Moore K; Mutch D; Robison K; Behbakht K; Waggoner S; Ghebre RG; Pearl M; Ramirez NC; Goodfellow P
Gynecol Oncol; 2015 Sep; 138(3):614-9. PubMed ID: 26144601
[TBL] [Abstract][Full Text] [Related]
25. Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.
Casanova J; Duarte GS; da Costa AG; Catarino A; Nave M; Antunes T; Serra SS; Dias SS; Abu-Rustum N; Lima J
Gynecol Oncol; 2024 Mar; 182():99-107. PubMed ID: 38262245
[TBL] [Abstract][Full Text] [Related]
26. Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients.
Bolivar AM; Luthra R; Mehrotra M; Chen W; Barkoh BA; Hu P; Zhang W; Broaddus RR
Mod Pathol; 2019 Mar; 32(3):405-414. PubMed ID: 30315273
[TBL] [Abstract][Full Text] [Related]
27. Corded and hyalinized endometrioid endometrial carcinoma with high-grade features: a clinicopathological and TCGA-based molecular analysis.
Travaglino A; Arciuolo D; Santoro A; Raffone A; Pedone Anchora L; Piermattei A; Martinelli M; Mollo A; Onori ME; Minucci A; Inzani F; Fanfani F; Insabato L; Zannoni GF
Virchows Arch; 2023 Apr; 482(4):671-678. PubMed ID: 36550216
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic Association and Prognostic Value of Microcystic, Elongated, and Fragmented (MELF) Pattern in Endometrial Endometrioid Carcinoma.
Kihara A; Yoshida H; Watanabe R; Takahashi K; Kato T; Ino Y; Kitagawa M; Hiraoka N
Am J Surg Pathol; 2017 Jul; 41(7):896-905. PubMed ID: 28418994
[TBL] [Abstract][Full Text] [Related]
29. Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression.
Huang HN; Kuo CW; Lin MC; Mao TL; Kuo KT
Appl Immunohistochem Mol Morphol; 2020 Apr; 28(4):284-289. PubMed ID: 30789355
[TBL] [Abstract][Full Text] [Related]
30. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
[TBL] [Abstract][Full Text] [Related]
31. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study.
Athanassiadou P; Athanassiades P; Grapsa D; Gonidi M; Athanassiadou AM; Stamati PN; Patsouris E
Int J Gynecol Cancer; 2007; 17(3):697-704. PubMed ID: 17504383
[TBL] [Abstract][Full Text] [Related]
32. Does tumor size have prognostic value in patients undergoing lymphadenectomy in endometrioid-type endometrial cancer confined to the uterine corpus?
Çakır C; Kılıç İÇ; Yüksel D; Karyal YA; Üreyen I; Boyraz G; Durmuş Y; Gültekin M; Özgül N; Karalök MA; Salman MC; Yüce K; Turan AT
Turk J Med Sci; 2019 Oct; 49(5):1403-1410. PubMed ID: 31650820
[TBL] [Abstract][Full Text] [Related]
33. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
Vermij L; Jobsen JJ; León-Castillo A; Brinkhuis M; Roothaan S; Powell ME; de Boer SM; Khaw P; Mileshkin LR; Fyles A; Leary A; Genestie C; Jürgenliemk-Schulz IM; Crosbie EJ; Mackay HJ; Nijman HW; Nout RA; Smit VTHBM; Creutzberg CL; Horeweg N; Bosse T;
Br J Cancer; 2023 Mar; 128(7):1360-1368. PubMed ID: 36690721
[TBL] [Abstract][Full Text] [Related]
34. Genomic landscape of endometrial carcinomas of no specific molecular profile.
Momeni-Boroujeni A; Nguyen B; Vanderbilt CM; Ladanyi M; Abu-Rustum NR; Aghajanian C; Ellenson LH; Weigelt B; Soslow RA
Mod Pathol; 2022 Sep; 35(9):1269-1278. PubMed ID: 35365770
[TBL] [Abstract][Full Text] [Related]
35. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
[TBL] [Abstract][Full Text] [Related]
36. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
[TBL] [Abstract][Full Text] [Related]
37. Corded and hyalinized endometrioid carcinoma: Summary of clinical, histological, immunohistochemical and molecular data.
Travaglino A; Arciuolo D; Santoro A; Raffone A; Raimondo D; Casadio P; Seracchioli R; Fulgione C; Guida M; Mollo A; Inzani F; Zannoni GF
Pathol Res Pract; 2023 Jul; 247():154515. PubMed ID: 37209572
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.
Han KH; Kim HS; Lee M; Chung HH; Song YS
Medicine (Baltimore); 2017 May; 96(21):e6976. PubMed ID: 28538399
[TBL] [Abstract][Full Text] [Related]
39. Microsatellite instability as a marker of prognosis: a systematic review and meta-analysis of endometrioid endometrial cancer survival data.
Xiao JP; Wang JS; Zhao YY; Du J; Wang YZ
Arch Gynecol Obstet; 2023 Feb; 307(2):573-582. PubMed ID: 35665848
[TBL] [Abstract][Full Text] [Related]
40. CTNNB1 -mutated High-grade Endometrioid Carcinoma With Extensive Squamous and Shadow Cell Differentiation Can Mimic Pilomatrix Carcinoma.
Mendoza R; Kertowidjojo E
Int J Gynecol Pathol; 2023 May; 42(3):325-326. PubMed ID: 35639408
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
